Incidence of benign upper respiratory tract infections, HSV and HPV cutaneous infections in inflammatory bowel disease patients treated with azathioprine

Alimentary Pharmacology and Therapeutics

Volumn 29, Issue 10, 2009, Pages 1106-1113

  Seksik, P ^a   Cosnes, J ^a   Sokol, H ^a   Nion Larmurier, I ^a   Gendre, J P ^a   Beaugerie, L ^a  

^a HÔPITAL SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BUDESONIDE; INFLIXIMAB; MESALAZINE; PREDNISONE; SALICYLIC ACID;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE EXACERBATION; ENTERITIS; FEMALE; HERPES; HERPES SIMPLEX VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; SKIN INFECTION; UPPER RESPIRATORY TRACT INFECTION; VERRUCA VULGARIS; WART VIRUS;

ADOLESCENT; ADULT; AGED; AZATHIOPRINE; COHORT STUDIES; FEMALE; HERPES SIMPLEX; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PROSPECTIVE STUDIES; RESPIRATORY TRACT INFECTIONS; YOUNG ADULT;

EID: 64849115125     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2009.03973.x     Document Type: Article

References (38)

1. Toruner M, Loftus EV Jr., Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008 134 : 929 36.
2. Fidder HH, Schnitzler F, Ferrante M, et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single center cohort study. Gut 2008. (in press).
3. Hutfless SM, Weng X, Liu L, Allison J, Herrinton LJ. Mortality by medication use among patients with inflammatory bowel disease, 1996-2003. Gastroenterology 2007 133 : 1779 86.
4. Ljung T, Karlen P, Schmidt D, et al. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut 2004 53 : 849 53.
5. Colombel JF, Loftus EV Jr., Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004 126 : 19 31.
6. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006 4 : 621 30.
7. Farrell RJ, Shah SA, Lodhavia PJ, et al. Clinical experience with infliximab therapy in 100 patients with Crohn's disease. Am J Gastroenterol 2000 95 : 3490 7.
8. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002 359 : 1541 9.
9. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004 350 : 876 85.
10. Viget N, Vernier-Massouille G, Salmon-Ceron D, Yazdanpanah Y, Colombel JF. Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis. Gut 2008 57 : 549 58.
11. Bunney MH, Benton EC, Barr BB, Smith IW, Anderton JL, Hunter JA. The prevalence of skin disorders in renal allograft recipients receiving cyclosporin A compared with those receiving azathioprine. Nephrol Dial Transplant 1990 5 : 379 82.
12. Spencer ES, Andersen HK. Clinically evident, non-terminal infections with herpesviruses and the wart virus in immunosuppressed renal allograft recipients. Br Med J 1970 3 : 251 4.
13. Koranda FC, Dehmel EM, Kahn G, Penn I. Cutaneous complications in immunosuppressed renal homograft recipients. JAMA 1974 229 : 419 24.
14. Spencer ES, Andersen HK. Viral infections in renal allograft recipients treated with long-term immunosuppression. Br Med J 1979 2 : 829 30.
15. Bouhnik Y, Lemann M, Mary JY, et al. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet 1996 347 : 215 9.
16. Present DH, Meltzer SJ, Krumholz MP, Wolke A, Korelitz BI. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med 1989 111 : 641 9.
17. Warman JI, Korelitz BI, Fleisher MR, Janardhanam R. Cumulative experience with short- and long-term toxicity to 6-mercaptopurine in the treatment of Crohn's disease and ulcerative colitis. J Clin Gastroenterol 2003 37 : 220 5.
18. Geerling BJ, Badart-Smook A, Stockbrugger RW, Brummer RJ. Comprehensive nutritional status in recently diagnosed patients with inflammatory bowel disease compared with population controls. Eur J Clin Nutr 2000 54 : 514 21.
19. Fleming CR. Nutrition in patients with Crohn's disease: another piece of the puzzle. JPEN J Parenter Enteral Nutr 1995 19 : 93 4.
20. O'Sullivan M, O'Morain C. Nutrition in inflammatory bowel disease. Best Pract Res Clin Gastroenterol 2006 20 : 561 73.
21. Rutgeerts P. A critical assessment of new therapies in inflammatory bowel disease. J Gastroenterol Hepatol 2002 17 (Suppl S176 85.
22. Beaugerie L, Carrat F, Bouvier AM, et al. The use of immunomodulators and biologics in inflammatory bowel diseases (IBD): a cross-sectional French nationwide cohort 2004-2005. Gastroenterology 2006 130 (4 Suppl. 2 A2.
23. Lennard-Jones JE, Shivananda S. Clinical uniformity of inflammatory bowel disease a presentation and during the first year of disease in the north and south of Europe. EC-IBD Study Group. Eur J Gastroenterol Hepatol 1997 9 : 353 9.
24. Cantorna MT, Zhu Y, Froicu M, Wittke A. Vitamin D status, 1,25-dihydroxyvitamin D3, and the immune system. Am J Clin Nutr 2004 80 (Suppl 6 1717 20.
25. Kandiel A, Lashner B. Cytomegalovirus colitis complicating inflammatory bowel disease. Am J Gastroenterol 2006 110 : 2857 65.
26. El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4 + count-guided interruption of antiretroviral treatment. N Engl J Med 2006 355 : 2283 96.
27. Roblin X, Serre-Debeauvais F, Phelip JM, et al. 6-tioguanine monitoring in steroid-dependent patients with inflammatory bowel diseases receiving azathioprine. Aliment Pharmacol Ther 2005 21 : 829 39.
28. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000 118 : 705 13.
29. Cuffari C, Li DY, Mahoney J, Barnes Y, Bayless TM. Peripheral blood mononuclear cell DNA 6-thioguanine metabolite levels correlate with decreased interferon-gamma production in patients with Crohn's disease on AZA therapy. Dig Dis Sci 2004 49 : 133 7.
30. Lemann M, Mary JY, Colombel JF, et al. A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. Gastroenterology 2005 128 : 1812 8.
31. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003 348 : 1681 91.
32. Leigh IM, Glover MT. Skin cancer and warts in immunosuppressed renal transplant recipients. Recent Results Cancer Res 1995 139 : 69 86.
33. de Villiers EM, Lavergne D, McLaren K, Benton EC. Prevailing papillomavirus types in non-melanoma carcinomas of the skin in renal allograft recipients. Int J Cancer 1997 73 : 356 61.
34. Bhatia J, Bratcher J, Korelitz B, et al. Abnormalities of uterine cervix in women with inflammatory bowel disease. World J Gastroenterol 2006 12 : 6167 71.
35. Venkatesan T, Beaulieu DB, Ferrer V, et al. Abnormal PAP smears, cervical dysplasia and immunomodulator therapy in women with with inflammatory bowel disease (IBD). Gastroenterology 2006 130 (4 Suppl. 2 A3.
36. Kane S, Khatibi B, Reddy D. Higher incidence of abnormal Pap smears in women with inflammatory bowel disease. Am J Gastroenterol 2008 103 : 631 6.
37. Wentzensen N, Vinokurova S, von Knebel Doeberitz M. Systematic review of genomic integration sites of human papillomavirus genomes in epithelial dysplasia and invasive cancer of the female lower genital tract. Cancer Res 2004 64 : 3878 84.
38. Agnantis NJ, Sotiriadis A, Paraskevaidis E. The current status of HPV DNA testing. Eur J Gynaecol Oncol 2003 24 : 351 6.